Suchergebnisse - "Mack, Timothy"

PubPharm (30)

1

In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma

enthalten in: Clinical pharmacology and therapeutics | 2022

von Ogasawara, K. | Lymp, J. | Mack, T. | +5

CommentIn: Clin Pharmacol Ther. 2022 Jul;112(1):11-15. - PMID 35716389

2

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM) : results from an interim analysis of an open-label, randomised, phase 3 trial

enthalten in: Lancet (London, England) | 2022

von Kamdar, M. | Solomon, S. | Arnason, J. | +19

CommentIn: Lancet. 2022 Jun 18;399(10343):2247-2249. - PMID 35717975

3

2021 White Paper on Recent Issues in Bioanalysis : TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness (

enthalten in: Bioanalysis | 2022

von Loo, L. | Harris, S. | Milton, M. | +59

4

2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness (Part 3– Recommendations on Gene Therapy, Cell Therapy, Vaccine Assays; Immunogenicity of Biotherapeutics and Novel Modalities; Integrated Summary of Immunogenicity Harmonization)

enthalten in: Bioanalysis | 2022

von Loo, L. | Harris, S. | Milton, M. | +58

5

In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B‐Cell Lymphoma

enthalten in: Clinical Pharmacology & Therapeutics | 2022

von Ogasawara, K. | Lymp, J. | Mack, T. | +5

6

Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma

enthalten in: Clinical pharmacokinetics | 2021

von Ogasawara, K. | Dodds, M. | Mack, T. | +3

ErratumIn: Clin Pharmacokinet. 2021 Jul 3;:. - PMID 34216384

7

Correction to : Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma

enthalten in: Clinical pharmacokinetics | 2021

von Ogasawara, K. | Dodds, M. | Mack, T. | +3

ErratumFor: Clin Pharmacokinet. 2021 Dec;60(12):1621-1633. - PMID 34125421

8

Resonance Raman Vibrational Mode Enhancement of Adsorbed Benzenethiols on CdSe Is Predominantly Franck-Condon in Nature and Governed by Symmetry

enthalten in: The journal of physical chemistry letters | 2021

von Mack, T. | Spinelli, J. | Andrews, M. | +1

9

Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma

enthalten in: Clinical pharmacokinetics | 2021

von Ogasawara, K. | Dodds, M. | Mack, T. | +3

10

Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma

enthalten in: Clinical pharmacokinetics | 2021

von Ogasawara, K. | Dodds, M. | Mack, T. | +3